1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lyka Labs Limited

Lyka Labs Limited

LYKALABS.BO
Lyka Labs LimitedIN flagBombay Stock Exchange
72.36
INR
+0.56
- -
2.54BMarket Cap
Lyka Labs Limited
LYKALABS.BO
(Bombay Stock Exchange)

Recent

price

72.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
64.47
- -
58.91
55.08
77.05
- -
47.65
21.82
22.54
19.47
23.39
63.99
30.69
31.88
38.37
35.98
35.57
Revenue per Share
1.12
- -
-0.33
-3.05
-2.29
- -
-2.56
-6.69
-1.95
-21.25
-4.03
13.59
-4.59
-0.75
2.22
-2.81
-2.78
Basic EPS, GAAP
4.04
- -
-0.76
11.49
9.14
- -
8.16
2.81
7.67
1.48
2.63
25
0.27
-2.26
-3.81
-1.65
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.5
- -
-10.54
-17.08
-19.37
- -
-19.36
-22.17
-21.93
-42.54
-46.27
-32.68
-36.47
-31.86
-26.17
10
9.88
Book Value per Share
43.86
- -
13.75
-11.42
-12.84
- -
-6.53
1.13
-0.59
-20.54
-22.79
-4.39
8.69
17.09
26.15
23.56
23.29
Tangible Book Value per Share
22
- -
22
22
22
22
22
26
28
28
29
29
29
33
36
36
36
Basic Weighted Avg Shares
1,391
- -
1,271
1,189
1,663
- -
1,050
564
642
555
671
1,836
883
1,051
1,385
1,284
1,284
Sales/Revenue/Turnover
15.76
- -
7.47
1.68
10.59
- -
11.92
-26.3
-14.34
-29.57
16.93
45.66
3.11
2.81
8.06
-9.43
-9.43
Operating Margin (%)
57
- -
117
88
109
- -
103
113
73
80
83
173
141
128
68
85
85
Depreciation Expense
24
- -
-7
-66
-49
- -
-55
-173
-56
-605
-116
390
-132
-25
80
-100
-100
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
35.11
- -
- -
28.69
- -
26.3
Effective Tax Rate (%)
1.73
- -
-0.56
-5.54
-2.98
- -
-5.27
-30.65
-8.64
-109.12
-17.22
21.24
-14.96
-2.37
5.79
-7.81
-7.81
Profit Margin (%)
353
-174
-205
-900
-936
- -
-1,027
-1,181
-497
-304
-208
-472
116
129
208
94
94
Working Capital
1,137
706
672
580
289
- -
349
41
784
1,272
1,509
617
648
431
188
230
230
LT Debt
1,425
756
698
560
466
- -
447
528
458
-151
-251
135
457
683
1,036
908
908
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.81
- -
- -
6.1
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
158.91
- -
- -
-18.77
- -
- -
Return on Capital (%)
10.64
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
132
- -
259
LT Borrowings
183
- -
230
LT Finance Leases
2
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
- -
36
Market Capitalization
3,476
2,752
1,615

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
606
- -
633
Cash, Cash Equivalents & STI
66
- -
69
Accounts Receivable, Net
371
- -
350
Inventories
115
- -
136
Total Current Liabilities
430
- -
539
Payables & Accruals
- -
- -
- -
ST Debt
132
- -
259
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.73%
-12.31%
Free Cash Flow
- -
-58.58%
-57.2%
Net Income, GAAP
- -
-259.92%
-225.21%
Sales/Revenue/Turnover
- -
33.03%
-7.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
229
280
326
217
1,051
2025
301
412
338
334
1,385
2026
330
367
307
280
1,284

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.57
-0.16
0.53
- -
-0.75
2025
0.4
0.58
0.75
0.49
2.22
2026
0.25
-0.94
- -
-2.13
-2.81

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Omega Therapeutics, Inc. (OMGA)
Anthera Pharmaceuticals, Inc. (ANTH)
Diagnamed Holdings Corp. (DMED.CN)
Calidi Biotherapeutics, Inc. (CLDI)
Telix Pharmaceuticals Limited (TLX)
EZZ Life Science Holdings Limited (EZZ.AX)
Business
Lyka Labs Limited manufactures and markets pharmaceutical formulations specializing in injectables, topicals, and contract manufacturing services. The company produces a wide range of products including emollients; topical steroids; antifungal agents; topical anti-bacterials; acne management solutions; dermatological formulations; pain killers; anti-aging creams; cleansing lotions; hair care products; anti-dandruff shampoos; sunscreens; anti-acne treatments; cosmeceuticals; anti-oxidants; proton pump inhibitors; nutraceuticals; anti-malarials; anti-bacterials; corticosteroid hormones; cephalosporins; dry powder injections; bone resorption inhibitors; liver disease treatments; antibiotics; and lyophilized products offered in forms such as injections, creams, ointments, foams, gels, and lotions. It provides contract manufacturing for large pharmaceutical companies and technical assistance including manufacturing know-how, stability testing data, impurity profiles, and BA/BE clinical studies across therapeutic areas like intensive care, gastroenterology, anti-infectives, anti-fungals, surgery care, cosmetology, urology, wound care, and anesthesia; operations span domestic and export markets from manufacturing facilities in Ankleshwar, Gujarat, and Tarapur, Maharashtra. Founded in 1976 and headquartered in Mumbai, India, Lyka Labs operates as a public company listed on BSE and NSE under ticker LYKALABS.BO with joint promoters including IPCA Laboratories holding approximately 27.76% stake. Recent developments include the acquisition of animal healthcare business from Agilis Healthcare Private Limited in 2023; launch of Tofacitinib ointment in fiscal 2023; entry into gynaecology and Assisted Reproductive Technology via new FertiNova division in fiscal 2025; and new product launches encompassing lyophilised injections, liquid injections, dry powder injections, and topical preparations such as ointments, creams, and lotions in 2025; additionally, the National Company Law Tribunal reserved its order on the amalgamation scheme with Lyka Exports Ltd as of August 2025.